On 23 June 2022 , sponsors from GILEAD Sciences in the US visited WMRU for 1 day. The visit was an opportunity for our visitors to see the WMRU site and talk to staff involved in conducting the study. WMRU will be conducting a Phase 3, Double-Blinded, Multicentre, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alfenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection
